MedPath

Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia

Phase 3
Completed
Conditions
Cervical Dystonia
Interventions
Biological: Botulinum toxin type A
Registration Number
NCT00447772
Lead Sponsor
Ipsen
Brief Summary

The aim is to demonstrate equivalent efficacy and safety in the treatment of the two most frequent forms of cervical dystonia (predominantly rotational torticollis and predominantly laterocollis) with the standard initial dose of 500 units Dysport®. The patients will be assigned to one of the two basic types of cervical dystonia, either predominantly rotational torticollis or predominantly laterocollis on the basis of clinical examination. This will determine which therapy is to be administered, using the clearly defined, structured injection protocols.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
516
Inclusion Criteria
  • De novo patients with cervical dystonia
  • Outpatient
  • Patients to be of age 18 years or older
  • Written informed consent to participate in the study
Exclusion Criteria
  • Pre-treatment of cervical dystonia with botulinum toxin
  • Pre-treatment with botulinum toxin for any indication other than cervical dystonia within the past 12 months
  • Pure retro- or antecollis
  • Neurological or other diseases which may affect head and neck motor function or neuromuscular transmission, e.g. polyneuropathy with pareses, myasthenia, myopathy, motor neurone diseases, Bekhterev's disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1Botulinum toxin type A-
Primary Outcome Measures
NameTimeMethod
Change From Baseline in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) at the First On-treatment Visit (Week 4 or Week 12)Baseline to Week 4 or Week 12 (up to 12 weeks)

The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:

* Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)

* Subscore B: duration of movement (values 1 or 2)

* Subscore C: severity and duration of shoulder elevation (range: 0-3 points)

* Subscore D: severity and duration of tremor (range: 0-4 points).

The total score was calculated as follows: total score = subscores (A x B) + C + D. The total score ranges between 0 and 25 points. A high total score represents severe CD.

The mean change in the total score of the Tsui rating scale (patient in the sitting position) between baseline (Week 0 visit) and the first on-treatment visit (Week 4 or Week 12 visit) is presented.

Secondary Outcome Measures
NameTimeMethod
Changes in the Items of the Patient Diary Based on Day-to-day Function and Activities, Pain and Duration of Pain Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12)Baseline to Week 4 and Week 12

The weekly recorded patient diary consists of the three items: Day-to-Day Capacities and Activities, Pain and Duration of Pain. Each item was rated by the patient on an 11-point scale ranging from 0 = no problems at all to 10 = most severe problems (the actual wording is adapted to each item in question).

The mean changes between the baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.

Change in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) Between Visit 1 (Week 0) and Visit 3 (Week 12)Baseline to Week 12

The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:

* Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)

* Subscore B: duration of movement (values 1 or 2)

* Subscore C: severity and duration of shoulder elevation (range: 0-3 points)

* Subscore D: severity and duration of tremor (range: 0-4 points).

The total score was calculated as follows: total score = subscores (A x B) + C + D. The total score ranges between 0 and 25 points. A high total score represents severe CD.

The mean change in the total score of the Tsui rating scale (patient in the sitting position) between baseline (Week 0 visit) and the Week 12 visit is presented.

Change in the Total Score of the Tsui Rating Scale (Patient Walking) Between Baseline (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12)Baseline to Week 4 and Week 12

The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:

* Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)

* Subscore B: duration of movement (values 1 or 2)

* Subscore C: severity and duration of shoulder elevation (range: 0-3 points)

* Subscore D: severity and duration of tremor (range: 0-4 points).

The total score was calculated as follows: total score = subscores (A x B) + C + D.

The total score ranges between 0 and 25 points. A high total score represents severe CD.

The mean changes in the total score of the Tsui rating scale (patient walking) between baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.

Change in the 4 Subscores of the Tsui Rating Scale (Patient in the Sitting Position) Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12)Baseline to Week 4 and Week 12

The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:

* Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)

* Subscore B: duration of movement (values 1 or 2)

* Subscore C: severity and duration of shoulder elevation (range: 0-3 points)

* Subscore D: severity and duration of tremor (range: 0-4 points).

A higher score for each subscale represents severe CD symptoms. The total score was calculated as follows: total score = subscores (A x B) + C + D. The total score ranges between 0 and 25 points. A high total score represents severe CD.

The mean changes in the subscores A to D of the Tsui rating scale (patient in the sitting position) between baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.

Change in the Craniocervical Dystonia Questionnaire (CDQ-24) Total Score and Subscores Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12)Baseline to Week 4 and Week 12

The CDQ-24 is a disease-specific quality of life (QoL) instrument and was assessed at Visits 1 to 3. It consists of 24 items investigating problems in daily living skills related to CD.

This instrument is based on 5 subscales: Stigma, Emotional well-being, Pain, Activities of daily living (ADL), Social/family life to which a number of the 24 items are assigned. There are five possible answers to each item representing increasing severity of impairment (scores 0 to 4). The total scores ranged from 0 to 96 (best to worst QoL). In order to obtain scores of the individual subscales, the total score of each subscale (sum of the individual item scores) was transformed linearly to a 0 to 100 scale (best to worst QoL).

The mean changes in the CDQ-24 total score between baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.

Categorical Changes in the Items of the Patient Diary Based on Day-to-day Function and Activities, Pain and Duration of Pain Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12)Baseline to Week 4 and Week 12

The weekly recorded patient diary consists of the three items: Day-to-Day Capacities and Activities, Pain and Duration of Pain. Each item was rated by the patient on an 11-point scale ranging from 0 = no problems at all to 10 = most severe problems (the actual wording is adapted to each item in question).

The following categorical changes between the baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented: Improvement, No change and Deterioration.

Number of Patients Without Pain and/or With a Reduction in Pain Based on a Global Assessment of Pain by the Investigator and by the Patient at Visit 2 (Week 4) and Visit 3 (Week 12)Week 4 visit and Week 12 visit

Global pain was assessed at Visit 2 (Week 4) and Visit 3 (Week 12); investigators and patients assessed change in global pain according to the following response categories:

1. = no pain (anymore)

2. = less pain

3. = no change

4. = more pain

The numbers of patients falling under each of these categories as assessed by the investigator and patient at Weeks 4 and 12 are presented.

Global Assessment of Efficacy by the Investigator and by the Patient at Visit 2 (Week 4) and Visit 3 (Week 12)Week 4 and Week 12

At Visit 2 (Week 4) and Visit 3 (Week 12) investigators and patients assessed global efficacy of injection of 500 U Dysport® according to the following response categories:

1. = very good

2. = good

3. = moderate

4. = insufficient

The numbers of patients falling under each of these categories as assessed by the investigator and patient at Weeks 4 and 12 are presented.

Trial Locations

Locations (83)

Städt. Krankenhaus Martha-Maria

🇩🇪

Halle, Germany

Gemeinschaftspraxis für Neurologie/Psychiatrie

🇩🇪

Lüneburg, Germany

Westpfalz-Klinikum GmbH

🇩🇪

Kaiserslautern, Germany

Krankenhaus der Barmherzigen Brüder

🇦🇹

Graz, Austria

NÖ LKH Grimmenstein-Hochegg

🇦🇹

Grimmenstein, Austria

Konventhospital der Barmherzigen Brüder

🇦🇹

Linz, Austria

Neurolog. Klinik des RWTH Aachen

🇩🇪

Aachen, Germany

Praxis für Neurologie

🇩🇪

Stralsund, Germany

Praxis für Neurologie und Psychiatrie

🇩🇪

Ostfildern, Germany

Sächsisches Krankenhaus

🇩🇪

Arnsdorf, Germany

Krankenhaus Hohe Warte

🇩🇪

Bayreuth, Germany

Neurologische Rehabilitationsklinik

🇩🇪

Beelitz, Germany

NRZ Neurologisches Rehabilitationszentrum Leipzig

🇩🇪

Bennewitz, Germany

Neurologisches Facharztzentrum am St.-Gertrauden-KH

🇩🇪

Berlin, Germany

Universitätsklinikum Charité, Campus Benjamin Franklin

🇩🇪

Berlin, Germany

Universitätsklinikum Charité, Campus Virchow-Klinikum

🇩🇪

Berlin, Germany

Krankenhaus Henningsdorf

🇩🇪

Berlin, Germany

Gemeinschaftspraxis für Neurologie

🇩🇪

Wolfenbüttel, Germany

SALUS Fachkrankenhaus Bernburg

🇩🇪

Bernburg, Germany

Berufsg. Kliniken Bergmannsheil

🇩🇪

Bochum, Germany

St.-Josef-Hospital

🇩🇪

Bochum, Germany

Medizinische Einrichtung Rhein. F.-Wilhelms-Universität Bonn

🇩🇪

Bonn, Germany

Zentralkrankenhaus Bremen-Ost

🇩🇪

Bremen, Germany

Klinikum Chemnitz gGmbH

🇩🇪

Chemnitz, Germany

Bezirksklinikum Mainkofen

🇩🇪

Deggendorf, Germany

Malteser Krankenhaus St. Anna

🇩🇪

Duisburg, Germany

University Hospital, Neurology Clinic

🇩🇪

Düsseldorf, Germany

HELIOS Klinikum Erfurt

🇩🇪

Erfurt, Germany

Alfried-Krupp-Krankenhaus

🇩🇪

Essen, Germany

Universitätsklinik Essen

🇩🇪

Essen, Germany

Kreiskrankenhaus Freiberg

🇩🇪

Freiberg, Germany

Bezirkskrankenhaus Günzburg

🇩🇪

Günzburg, Germany

Klinikum Ambrock

🇩🇪

Hagen, Germany

Uniklinik Jena

🇩🇪

Jena, Germany

Universitätsklinikum Kiel

🇩🇪

Kiel, Germany

Kath. Klinikum/Brüderkrankenhaus

🇩🇪

Koblenz, Germany

Neurologische Praxis

🇩🇪

Straubing, Germany

Universitätsklinikum Leipzig

🇩🇪

Leipzig, Germany

Klinikum Lippe-Lemgo GmbH

🇩🇪

Lemgo, Germany

Klinikum der Stadt Ludwigshafen

🇩🇪

Ludwigshafen, Germany

Universitätsklinikum Münster

🇩🇪

Münster, Germany

Uniklinik Erlangen

🇩🇪

Erlangen, Germany

O.Ö. Landes-Nervenklinik Wagner-Jauregg

🇦🇹

Linz, Austria

Praxis für Anästhesiologie

🇩🇪

Ahaus, Germany

Klinikum für Rehabilitation

🇩🇪

Bad Oeynhausen, Germany

Neurologische Klinik GILEAD im Evang. KH Bielefeld EVKB

🇩🇪

Bielefeld, Germany

Landesklinik Eberswalde

🇩🇪

Eberswalde, Germany

Universitätsklinikum Carl Gustav Carus

🇩🇪

Dresden, Germany

Zentrum für Neurologie

🇩🇪

Giessen, Germany

Sächsisches Krankenhaus für Psychiatrie, Psychotherapie und Neurolgie

🇩🇪

Großschweidnitz, Germany

Katholisches Krankenhaus Hagen

🇩🇪

Hagen, Germany

Universitätskliniken des Saarlandes

🇩🇪

Homburg, Germany

Neurologische Uniklinik

🇩🇪

Hannover, Germany

Klinikum Koeln-Merheim

🇩🇪

Koeln, Germany

Universitätsklinikum

🇩🇪

Rostock, Germany

Neurologisches Krankenhaus München

🇩🇪

München, Germany

Kliniken Maria Hilf GmbH

🇩🇪

Mönchengladbach, Germany

Klinikum Minden

🇩🇪

Minden, Germany

Klinikum rechts der Isar

🇩🇪

München, Germany

Praxis für Neurologie und Nervenheilkunde

🇩🇪

Neubrandenburg, Germany

Evangelisches Krankenhaus Oldenburg

🇩🇪

Oldenburg, Germany

St.-Josefs-Krankenhaus

🇩🇪

Potsdam, Germany

Klinikum Nürnberg-Süd

🇩🇪

Nürnberg, Germany

St. Vincenz-Krankenhaus GmbH

🇩🇪

Paderborn, Germany

Klinikum Ernst von Bergmann

🇩🇪

Potsdam, Germany

Zentrum für Psychiatrie Weissenau

🇩🇪

Ravensburg, Germany

Knappschafts-Krankenhaus

🇩🇪

Recklinghausen, Germany

Klinikum Uckermark GmbH

🇩🇪

Schwedt/Oder, Germany

Evang.-Freichkirchl. Krankenhaus

🇩🇪

Rüdersdorf, Germany

EMSA

🇩🇪

Singen, Germany

HELIOS Kliniken Schwerin

🇩🇪

Schwerin, Germany

Landesklinik Teupitz

🇩🇪

Teupitz, Germany

Landesfachkrankenhaus für Psychatrie und Neurologie

🇩🇪

Stadtroda, Germany

Asklepios Kliniken Schildautal

🇩🇪

Seesen, Germany

Zentrum für Neurologie und Hertie-Institut für Klinische Hirnforschung

🇩🇪

Tübingen, Germany

Klinikum Weiden

🇩🇪

Weiden, Germany

Stiftung Deutsche Klinik für Diagnostik

🇩🇪

Wiesbaden, Germany

Klinikum Wuppertal

🇩🇪

Wuppertal, Germany

Medizinisches Studienzentrum

🇩🇪

Würzburg, Germany

Universitätsklinikum Würzburg

🇩🇪

Würzburg, Germany

Paracelsus Klinik

🇩🇪

Zwickau, Germany

Klinikum Mannheim

🇩🇪

Mannheim, Germany

Univ.-Klinik für Neurologie

🇦🇹

Innsbruck, Austria

© Copyright 2025. All Rights Reserved by MedPath